Target
oriented
drug
development
Pipeline
Development Status
Potential First-in-Class
& Best-in-Class NASH Drug
ㆍSubstantial potential market opportunity
ㆍDifferentiated mechanism of action
ㆍStrong efficacy data of FGF21 including:
✓ The levels of hepatic triglycerides and lipids
✓ The degree of vacuolization of liver
✓ Validated Immunogenicity
Patented FGF21 design
& Manufacturing method
ㆍFive point-mutations for high affinity toward
β-Klotho and enhanced receptor activation
ㆍThe ever-first findings of
ㆍThe temperature-responsive structural reversib
ility of FGF21 and
ㆍHeating-based purification of active FGF21
ㆍThese findings can be applied to FGF21 analogs t
hat are under therapeutic development
Experienced & Validated Team in the protein research field
ㆍSun-shin Cha (a full professor at Ewha Woman
University) leads a competitive protein research group
ㆍThree LO experiences for β-lactamase inhibitors,
human DJ-1 (park7), and FGF21 (to TODD) in Korea
ㆍAbout 130 publications including Nature, Immunity,
Nature Genetics, Nature Chemical Biology,
Nature Communications, EMBO J, PNAS, Angewandte
Chemie, Nucleic Acid Research, JBC, etc.
News & Media
TODD is a “drug development company” that designs and develops protein-based and synthetic chemical pharmaceuticals based on innovative core technologies and business areas.
We are always striving to provide innovation and high-quality products and services, and we aim to grow into a global pharmaceutical company through continuous research and development and cooperation.
TODD will always meet the diverse needs of customers based on the best quality and innovative technology, and pursue continuous development for a better future.
